✦ LIBER ✦

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study

✍ Scribed by Sten Nilsson; Lars Franzén; Christopher Parker; Christopher Tyrrell; René Blom; Jan Tennvall; Bo Lennernäs; Ulf Petersson; Dag C Johannessen; Michael Sokal; Katharine Pigott; Jeffrey Yachnin; Michael Garkavij; Peter Strang; Johan Harmenberg; Bjørg Bolstad; Øyvind S Bruland

Book ID: 117784333
Publisher: The Lancet
Year: 2007
Tongue: English
Weight: 202 KB
Volume: 8
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(07)70147-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, dose–response, multicenter

A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer

✍ S. Nilsson; P. Strang; A.K. Aksnes; L. Franzèn; P. Olivier; A. Pecking; J. Staff 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 512 KB

Safety and Efficacy of the Specific Endo

Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial

✍ Nicholas D. James; Armelle Caty; Michael Borre; Bernard A. Zonnenberg; Philippe 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 1000 KB

Final safety and efficacy analysis of th

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial

✍ Nicholas D. James; Armelle Caty; Heather Payne; Michael Borre; Bernard A. Zonnen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 428 KB

Effect of endothelin-A receptor blockade

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD: J Clin Oncol 2003;21:679–689

✍ Donald L Trump 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 21 KB